RELEVANCE OF COVID-19 IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
Keywords:
chronic viral hepatitis, COVID-19, cytokine/IL-6, hypocoagulation, C-reactive protein (CRP)Abstract
In the study of patients with COVID-19, those with CVH (CCHF) had increased levels of proinflammatory cytokine/IL-6, medium molecular weight peptides, and C-reactive protein (CRP). These markers were found to be correlated with slow disease progression, prolonged persistence of symptoms, and unfavorable treatment outcomes. Administering high-molecular-weight heparin without establishing the presence of cardiovascular disease in a patient with COVID-19 and without studying hemostasis data can worsen the patient's condition due to the accelerated development of hypocoagulation on the background of thrombophilia. It has been established that the presence of obesity of II-III degree, pathologies related to the cardiovascular system, bronchial asthma, and diabetes mellitus in patients with COVID-19 contributes to a more severe course of the disease. The long-term preservation of an elevated level of C-reactive protein in patients with CCHF reflects ongoing tissue damage and prolongation of the severity of the inflammatory process. This can serve as a diagnostic and prognostic marker for the need for long-term rehabilitation.
References
Cadieux G., Campbell J., Dendukuri N. Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection. CMAJOpen 2016; 4(4): E737–E745.
Ha S., Totten S., PoganyL., Wu J., Gale-Rowe M. Hepatitis Cin Canada and the importance of risk-based screening. Can Commun Dis Rep 2016; 42(3): 57-62.
Missiha S.B., Ostrowski M., Heathcote E.J. Disease Progression in Chronic Hepatitis C: Modifiable and Non modifiable Factors. Gastroenterology 2008; 134 (6): 1699–1714.
Sarin S.K, Kumar M. Natural history of HCV infection. Hepatol Int. 2012; 6 (4): 684–695.
Габриэлян Н.И., Липатова В.И. Количественный метод определения СМП в сыворотке крови. Лаб. дело.- 1989.-№4.-С.24-28 (in Russ).
Статья поступила в редакцию 03.03.2024; одобрена после рецензирования 25.04.2024; принята к публикации 26.04.2024.
The article was submitted 03.03.2024; approved after reviewing 25.04.2024; accepted for publication 26.04.2024.
Информация об авторах:
Имамова Ильмира Абдуллаевна- к.м.н., старший преподователь. Ташкентская медицинская академия., Ташкент, Узбекистан. Е-mail: info@tma.uz ORCID: https://orcid.org/0000-0003-3247-2048
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Имамова И.А. — сбор и обработка материала, написание текста
Information about the authors:
Ilmira Abdullaevna Imamova - a senior lecturer., PhD., Tashkent Medical Academy. Tashkent., Uzbekistan. E-mail info@tma.uz or through her ORCID profile at https://orcid.org/0000-0003-3247-2048.
Funding: This work did not receive any special funding.
Conflict of Interest: The authors declare no conflicts of interest related to the publication of this article.
Imamova I.A. collected and processed the material and wrote the text, while
